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OPINION 
The BAFFling effects of rituximab in lupus: danger ahead?  
Michael R. Ehrenstein and Charlotte Wing 
 
Abstract  
Sub-optimal trial design and concurrent therapies are thought to account for the unexpected 
failure of two rituximab clinical trials in patients with systemic lupus erythematosus (SLE). 
However, in this Perspective we propose an alternative explanation: that rituximab can 
trigger a sequence of events that exacerbates disease in some lupus patients. Post-rituximab 
SLE flares that are characterized by high anti-dsDNA antibodies are associated with elevated 
circulating BAFF (B-cell-activating factor), and a high proportion of plasmablasts within the 
B cell pool. BAFF not only perpetuates autoreactive B cells (including plasmablasts), 
particularly when B-cell numbers are low, but also stimulates T follicular helper (TFH) cells. 
Moreover, plasmablasts and TFH cells promote each others’ formation.  Thus, repeated 
rituximab infusions can result in a feedback loop characterized by ever-rising BAFF levels, 
surges in autoantibody production and worsening of disease. We argue that B-cell depletion 
should be swiftly followed by BAFF inhibition in patients with SLE. 
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Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease associated 
with substantial morbidity and some mortality1 A considerable body of evidence implicates B 
cells in the pathogenesis of SLE, and successful use of the B-cell-depleting agent rituximab 
in patients with SLE has been reported in numerous open-label studies (reviewed elsewhere)2. 
However, two randomized controlled trials of rituximab therapy in patients with SLE did not 
meet their primary end points: EXPLORER3, 4 and LUNAR5. It has been cogently argued that 
various aspects of trial design could account for these failures2, and accordingly further trials 
of rituximab in patients with SLE are now planned or underway. However in this Perspective, 
we propose a different explanation for the failure of these trials: specifically that rituximab 
therapy triggers a surge in BAFF (B-cell-activating factor, also known as TNF ligand 
superfamily member 13B or BLyS) which exacerbates disease in some patients with SLE.  
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Plasmablasts and SLE flare  
Patients with SLE respond differentially to rituximab according to their anti-dsDNA antibody 
levels, the duration of B-cell depletion, and the type of B cell that dominates the early 
repopulation phase. Disease returns most quickly in patients whose B cells repopulate 
rapidly6. In this section, we discuss the evidence that an increased frequency of circulating 
plasmablasts found in the B-cell pool following rituximab therapy is associated with lupus 
flares characterised by high anti-DNA antibody levels.  
Among patients with SLE who relapse after rituximab therapy, those with high anti-
dsDNA antibody levels have significantly fewer B-cells at the time of relapse  compared to 
those who flare without increased anti-DNA antibodies6.  Post-rituximab flare in patients 
with high anti-dsDNA antibodies was characterized by an increased percentage of circulating 
plasmablasts within the repopulating B cell pool, compared to patients who remained in 
remission and those who relapsed without increased anti-DNA antibodies6. Elevated 
plasmablast numbers following rituximab treatment has been associated with a shorter 
interval to subsequent relapse7. An increased frequency of peripheral blood plasmablasts is 
also associated with active disease in patients with SLE, and this B-cell subset is considered 
to have a role in driving disease8. The number of CD27high plasmablasts in patients with SLE 
is strongly correlated with SLE disease activity indices, and with anti-dsDNA antibodies9. 
Despite low overall B-cell numbers following B-cell depletion therapy, a high percentage of 
plasmablasts, presumably producing autoantibodies, within the residual B-cell pool could 
trigger an SLE flare. Patients who have a high proportion of plasmablasts also often have few 
transitional B cells, a compartment rich in regulatory B cells. Deficiency in this suppressive 
population could contribute to an earlier relapse in disease10.  
Human peripheral blood plasmablasts promote the differentiation of T follicular 
helper (TFH) cells, partly via IL-6
11, 12. TFH cells can in turn stimulate plasmablast formation, 
thereby creating a positive feedback loop and perpetuating disease (Fig. 1). In support of 
these observations in humans, differentiation of TFH cells in mouse models of infection is also 
dependent upon B-cell production of IL-613. The frequency of TFH cells correlates with 
plasmablast numbers, anti-dsDNA antibody levels and disease activity (particularly the 
severity of glomerulonephritis) in SLE14-16. Moreover, circulating TFH cells in patients with 
SLE are capable of driving differentiation of B cells into plasmablasts in vitro17. Ectopic 
clusters of TFH cells and B cells are present in the inflamed kidneys of patients with SLE and, 
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together with conventional germinal centre formation, probably contribute to the 
pathogenesis of this disease18. Evidence from animal models of lupus suggests that abnormal 
germinal centre activity and TFH cells orchestrate the generation of lupus-related 
autoantibodies. Mice homozygous for Rc3h1san (the san allele encoding the sanroque form of 
roquin-1, a RING-type ubiquitin ligase) develop germinal centres, excessive TFH cell 
numbers and features of lupus such as glomerulonephritis 19. Adoptive transfer of sanroque-
expressing TFH cells into wild-type recipients resulted in spontaneous germinal centre 
formation, underscoring the direct role of TFH cells in lupus-associated autoimmunity. In 
another lupus model, BXD2 mice, TFH cells drive the increased autoantibody levels and 
enhanced germinal centre B-cell responses through an IL-21 dependent mechanism20. 
 
Rituximab disturbs BAFF homeostasis  
The predominance of plasmablasts in the repopulated B cells (in the context of overall B-cell 
lymphopenia) and the potential of plasmablasts to drive TFH cell formation might encourage 
clinicians to consider the use of increasing doses of rituximab, as has been suggested for 
rheumatoid arthritis (RA)21. However, post-rituximab SLE flares that are accompanied by 
elevated anti-dsDNA antibody levels and low B-cell numbers are closely associated with 
increased BAFF levels22. BAFF is an important physiological mediator of B-cell 
homeostasis, and has a role in regulating survival and self-tolerance during B-cell 
development23. Serum BAFF is elevated immediately after rituximab therapy in patients with 
SLE, but initial reports indicated that BAFF levels reverted to pretreatment values by 6 
months, and was not associated with clinical relapse24. Similar observations were made in 
patients with RA treated with rituximab, in whom BAFF levels normalized upon B-cell 
repopulation and did not correlate with disease relapse25. Although these early data did not 
suggest that elevated BAFF levels directly contributed to disease flare post-rituximab the 
repopulated B-cells could be initially skewed towards an autoreactive repertoire23. Whether a 
transient elevation in serum BAFF that returned to baseline prior to a relapse in disease  
would have an enduring adverse impact upon the B-cell repertoire remained uncertain. 
However, a subsequent study clearly showed that elevated BAFF levels can persist in patients 
with SLE but only in those who relapse with high anti-dsDNA antibody levels after rituximab 
treatment22, and that these high BAFF levels are likely to provide an environment in which 
autoreactive B cells flourish. By contrast, patients who flare following B-cell depletion but do 
not display high anti-dsDNA antibody levels do not have elevated serum BAFF.  
Studies in transgenic mice suggest that survival of autoreactive B-cell clones requires 
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higher levels of BAFF than does maintenance of the self-tolerant population26. Consequently, 
elevated BAFF lowers the stringency of B-cell selection and thereby rescues autoreactive 
clones that would otherwise be deleted27-29. In addition, BAFF supports the survival of 
plasmablasts,30 whereas BAFF inhibition reduces the differentiation of naive marginal zone B 
cells into plasmablasts31. Increased production of BAFF by dendritic cells promotes 
plasmablast formation in patients with SLE32. Rising levels of BAFF following rituximab 
therapy, coupled with reduced B-cell competition, could remove the brakes on autoreactive B 
cells (including plasmablasts) and thereby trigger an SLE flare (Fig. 2).  
BAFF was first linked to lupus-like autoimmunity following the finding that mice 
engineered to constitutively express BAFF develop a lupus-like syndrome associated with 
autoantibodies against nuclear antigens33, 34. Serum BAFF is elevated in lupus-prone NZB/W 
F1 mice and treatment of these mice with a BAFF antagonist ameliorated the progression of 
disease and improved survival35. Clinical studies demonstrate that BAFF is overexpressed, 
either intermittently or persistently, in many patients with SLE36, 37, and that levels of BAFF 
correlate with serological and clinical indices of disease activity in such patients38, 39. 
Myeloid cells, B and T cells, and neutrophils are all thought to contribute to the BAFF excess 
observed in SLE, which is induced by a variety of signals (including type I interferons40-42 
and TLR9 activation43). In addition, the B-cell lymphopenia associated with active SLE8 
could also trigger a compensatory release of BAFF. Belimumab, a BAFF-neutralizing 
monoclonal antibody, has shown modest efficacy in phase 3 clinical trials, in patients with 
joint and skin manifestations of SLE, validating BAFF as an important novel therapeutic 
target44. Another therapeutic reagent that targets BAFF, tabalumab, has also shown some 
promise in phase 3 clinical trials, although a number of key end points were not achieved45, 46. 
Some debate remains as to which of the interactions between BAFF and its three 
receptors holds the key to pathogenicity in SLE, and it is possible that they all contribute. 
Knockout studies in the NZM 2328 lupus-prone mouse have demonstrated that any single 
BAFF receptor is dispensable to the development of lupus.47 In vitro, BAFF has a 
proliferative effect on human mesangial cells via a BAFF–BAFF-R (also known as TNF 
receptor superfamily member 13C) interaction on the cell membrane48. In BAFF transgenic 
mice, deletion of TACI (also known as TNF receptor superfamily member 13B) on B cells 
protects against BAFF-mediated autoimmunity49. The least well-studied BAFF receptor 
(BCMA, also known as TNF receptor superfamily member 17) has a role in maintaining the 
survival of plasma cells,50 but its exact role in autoimmunity remains unclear51, 52. The 
generation of two different BCMA-deficient lupus-prone mouse models, B6.lpr Tnfrsf17–/– 
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and Nba2 Tnfrsf17–/– mice, which were expected to display milder disease than their wild-
type counterparts, in fact developed accelerated proliferation of B cells and plasma cells with 
increased autoantibody production and early lethality53. These observations suggest that in 
the context of autoimmunity, BCMA might in fact have an inhibitory role in B-cell 
activation53. However, BCMA deficiency in an alternative mouse model of lupus (NZM 
2328) resulted in similar morbidity to that observed in the wild-type NZM 2328 mouse47. 
Interestingly, subsequent experiments in these mice with varying pairs of BAFF receptor 
deletions resulted in different clinical courses of disease: mice with BAFF-R and TACI 
deletions, or BAFF-R and BCMA deletions, developed attenuated disease54.  
BAFF is also involved in regulation of TFH cells (Fig. 1). BAFF directly stimulates T-
cell proliferation and cytokine production55, 56; moreover, BAFF blockade in BCMA-
deficient, autoimmune disease-prone mice resulted in markedly reduced numbers of TFH cells 
(as well as reductions in germinal centre B cells and plasma cells) in the spleens of these 
mice, suggesting an important role for BAFF in the maintenance of TFH cells in the germinal 
centre57. However, administration of recombinant BAFF to BCMA-deficient mice (but not to 
wild-type control mice) increased the numbers of total and germinal centre TFH cells, 
germinal centre B cells and plasma cells. These findings suggest that in the absence of 
BCMA, excessive BAFF signalling via its two other receptors (BAFF-R, TACI, or both) 
could be responsible for the proliferation of TFH cells, germinal centre B cells and splenic 
plasma cells.  
Analysis of human TFH cells from patients with SLE did not reveal any evidence of 
BCMA expression; however, the percentage of TFH cells that expressed BAFF-R was 
increased in TFH cells from patients with SLE compared with those from healthy donors
57. 
We might speculate, therefore, that signals transduced through BAFF-R on human TFH cells 
could lead to uncontrolled TFH cell differentiation and accumulation, whereas (at least in 
mice) BCMA has a role in downregulating TFH. Local BAFF production by TFH cells has 
been identified as an important factor promoting the survival of high-affinity B cells in the 
germinal centre58. If this same mechanism is present in an autoreactive setting, it could foster 
diseases such as SLE59. Thus, development of therapies that target BAFF receptors might be 
an alternative strategy to BAFF blockade in SLE, but careful analysis of its effects in both 
mice and humans will be required if untoward effects are to be avoided. 
These various lines of evidence suggest, therefore, that B-cell depletion further 
distorts BAFF homeostasis in patients with SLE, leading to a closer association between 
BAFF levels and disease exacerbation than is evident in patients with SLE who have not been 
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treated with rituximab. This situation might arise because the loss of B cells following 
rituximab therapy largely removes the major ‘users’ of circulating BAFF, thereby raising 
serum BAFF levels60. This mechanism, as well as the increased production of BAFF that 
drives B-cell repopulation, could contribute to the increased levels of BAFF observed in 
patients who relapse after rituximab therapy compared to both those in remission and those 
who experience flare prior to B-cell depletion22 (Fig. 2).  
Changes in serum BAFF levels also correlate positively with changes in anti-dsDNA 
antibody levels during relapse or remission after rituximab treatment: higher BAFF levels 
during flare were associated with higher anti-dsDNA levels22. Of greater concern is that 
consecutive flares in a proportion of previously rituximab-treated patients were characterized 
by incremental increases in both anti-dsDNA antibody and BAFF levels following each cycle 
of rituximab22, (Fig. 3). Indeed, approximately half of patients who relapse following 
rituximab therapy show increasing levels of BAFF and a rise in anti-dsDNA antibody 
levels22. These effects appear to be most marked in a subset of patients who undergo multiple 
cycles of rituximab therapy22, highlighting a potential danger of successive rituximab 
treatments for some patients, especially as the most recent analysis of the efficacy of repeated 
infusions of rituximab revealed that one-third of the patients studied underwent three or more 
cycles of B-cell-depletion therapy61. We envisage the existence of a BAFF-driven feedback 
loop between plasmablasts and TFH cells, gaining ever-increasing momentum with successive 
rituximab infusions, and leading to worsening disease and accumulating organ damage. This 
may only apply to patients whose post-rituximab flare is associated with anti-DNA 
antibodies. Further work is needed to establish the effects of repeated rituximab infusions in 
patients with SLE, and to elucidate the mechanisms controlling BAFF levels, B-cell 
repopulation and disease relapse. 
A comparison of the repeated use of B-cell depleting therapy in SLE and in RA (in 
which rituximab has proven efficacy) reveals differences with respect to BAFF levels after 
rituximab treatment. Firstly, although BAFF levels are elevated in rituximab-treated patients 
with RA, each successive flare does not lead to further incremental increases in BAFF levels 
at onset of the next relapse62. The authors concluded that elevated serum BAFF levels were 
not related to the presence of absence of active disease62. These differences might contribute 
to why rituximab’s effectiveness, including in patients receiving repeated courses of 
treatment, has been demonstrated in RA but not in SLE. 
 
The case for sequential therapy  
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The principle of targeting more than one pathogenetic mechanism to increase the efficacy of 
targeted therapies is gaining traction in several autoimmune disease settings. For example, 
multiple pathways could be targeted sequentially, to first induce remission and then to restore 
a state of immune tolerance to prevent reactivation of the disease process63. A thorough 
understanding of the mechanism of action of each biological therapy is important in deciding 
which combinations will work best to prevent resurgence of disease.  
The above evidence suggests that the increasing BAFF levels that can arise following 
repeated cycles of rituximab have the potential to create more aggressive disease and 
consequent organ damage for some patients with SLE. Thus, rituximab therapy might 
temporarily improve the disease but its repeated use could worsen patients’ long term 
outcomes. An obvious solution would be to combine rituximab with BAFF blockade, an 
approach that has been previously proposed to achieve sustained remission in patients with 
SLE60. In mice, a combination of B-cell depletion and BAFF inhibition removes B cells in 
the marginal zone and follicular compartments more effectively than either treatment alone64. 
Also in mice, a combination of B-cell depletion therapy and BAFF blockade was superior to 
B-cell depletion alone with respect to reducing the numbers of plasmablasts and plasma cells, 
as well as reducing disease severity, in three different models of lupus65. 
Belimumab has been used prior to rituximab treatment in patients with chronic 
lymphoid leukaemia. In this disease, the ability of natural killer (NK) cells to directly lyse 
malignant cells and to mediate antibody-dependent cell-mediated cytotoxicity is 
compromised. NK cells produce BAFF, particularly when activated, and this increase in 
BAFF enhances the metabolic activity of malignant cells and reduces their susceptibility to 
both direct NK-cell lysis and rituximab-induced antibody-dependent cell-mediated 
cytotoxicity.66 Pretreatment with belimumab restored the sensitivity of malignant cells to 
rituximab-induced NK cell lysis.  
We propose that post-rituximab flares characterized by increasing BAFF levels, low 
B-cell numbers and high anti-dsDNA antibodies could be effectively addressed by 
administration of a BAFF-blocking agent immediately following B-cell depletion. Two trials 
of rituximab followed by belimumab therapy are currently recruiting: the open-label 
CALIBRATE study (Rituximab and Belimumab for Lupus Nephritis)67 and the SYNBIoSe 
study (Synergetic B-Cell Immodulation in SLE)68. A third randomized and double-blinded 
trial (unlike the other two which are open label) comparing belimumab with standard care in 
patients after rituximab therapy (BEAT-LUPUS) will soon be recruiting in the UK. In 
addition to determining the efficacy of sequential B-cell-depleting and anti-BAFF therapy, 
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these studies will provide a useful opportunity to dissect B-cell kinetics in rituximab-treated 
patients. Comparing the phenotype, clonal relationships, and the associated autoreactivity of 
B cells present at relapse and remission in rituximab-treated patients with SLE, with or 
without the addition of belimumab, will yield insight into the mechanisms of relapse and 
whether tolerance can be restored. As an alternative to belimumab, conventional 
immunosuppressive agents (such as mycophenolate mofetil) could potentially be 
administered to suppress the surge in BAFF levels post-rituximab, although our observations 
of incremental rises in BAFF levels usually occur on the background of either mycophenolate 
or azathioprine therapy. 
Although belimumab and rituximab were administered together in preclinical studies 
in mice64,65, it is unclear whether simultaneous administration is required or indeed the safest 
approach. The duration and magnitude of B-cell depletion induced by simultaneous 
administration of combinations of belimumab and rituximab is unknown in patients. BAFF 
levels rise soon after rituximab therapy but it is very unusual for patients to experience an 
SLE flare before their B cell levels have risen to >0.01×109 cells/l, or before 2 months after 
rituximab therapy6. We would accordingly recommend a flare-prevention strategy based on 
administration of belimumab 2 weeks after the final rituximab infusion  (although we 
recognize that these timings might need to be revised). Such sequential administration might 
prevent the surge in BAFF levels from altering the B-cell autoreactive repertoire. Whether 
this approach would increase the patient’s risk of infection is also unknown, although no 
safety signal was seen in mouse studies using combination B cell depletion and BAFF 
inhibition64,65. It would be important to monitor B-cell repopulation and immunoglobulin 
levels in patients receiving belimumab after rituximab as surrogate indicators of safety with 
respect to infection. Moreover, patient’s responses to vaccination during and after this 
combination treatment are likely to be limited, and patients should be advised to receive 
relevant vaccines some time before rituximab and belimumab are administered. 
 
Conclusions  
Successive disease flares after rituximab therapy in patients with SLE can be marked by 
rising levels of anti-dsDNA antibodies, a high frequency of plasmablasts, and mounting 
levels of BAFF. Sequential treatments with rituximab appear to cause these incremental 
increases in BAFF levels — which, in the setting of low B-cell numbers, enable autoreactive 
B cells to thrive. BAFF can also promote the formation of plasmablasts and TFH cells and, 
therefore, accelerate germinal centre activity, leading to the expansion of autoantibody-
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secreting plasma cells. Compounding this effect, the early increase in plasmablast numbers 
after B-cell-depletion therapy enhances the formation of TFH cells, creating a positive 
feedback loop that perpetuates antibody-driven inflammation in SLE. This sequence of events 
could explain why some patients with SLE fail to respond (or become refractory) to B-cell 
depletion therapy.  
The evidence presented above provides the rationale for the addition of BAFF 
inhibition to prevent flares in rituximab-treated lupus patients. Encouraging results have been 
obtained using this approach in animal models, and randomized controlled trials in humans 
are underway or about to start. If successful, this new treatment paradigm might prove a 
major leap forward in controlling SLE and inducing sustained remission in these patients. 
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Figure legends  
Figure 1: BAFF activates and perpetuates interactions between plasmablasts and TFH 
cells in SLE. SLE is characterized by increased proportions of circulating plasmablasts and 
TFH cells. Dendritic cells in patients with SLE produce BAFF, which stimulates plasmablast 
differentiation. The role of plasmablasts is not limited to the production of pathogenic 
autoantibodies; they also induce the differentiation of TFH cells, via IL-6, which in turn 
stimulates plasmablast formation, via IL-21. TFH cells from lupus-prone mice express both 
BAFF-R and BCMA, but TFH cells from patients with SLE have so far been shown to express 
only BAFF-R. Thus, the BAFF surge that is characteristic of post-rituximab flares of SLE 
serves to perpetuate plasmablasts and TFH cells, creating a positive feedback loop and 
worsening antibody-driven inflammation. Furthermore, TFH cells in germinal centres can also 
produce BAFF, thereby promoting the survival of high-affinity germinal centre B cells. 
Excess BAFF produced by TFH cells might provide the necessary survival signals to foster 
autoreactive B cells in SLE. 
 
Figure 2: The relationship between BAFF, ant-DNA antibodies and B-cell numbers in 
SLE, before and after rituximab therapy. Active SLE (SLE relapse pre-rituximab therapy) 
is associated with a modest B-cell lymphopenia and an increased proportion of plasmablasts, 
compared with the situation in healthy individuals. Those patients who flare after treatment 
with rituximab with elevated anti-DNA antibodies also have high BAFF levels, often with 
very low B cell numbers among which autoreactive plasmablasts predominate. This 
phenomenon can be compounded by repeated rituximab infusions (see also Figure 3). By 
contrast, patients who remain in remission after B-cell depletion have moderate BAFF levels. 
Understanding the relationship between BAFF levels, B cell subsets and SLE flare will be 
crucial for the appropriate selection of therapy in these patients. 
 
Figure 3: The effects of repeated rituximab infusions on anti-dsDNA antibody levels in a 
patient with SLE. The patient presented at the age of 26 years with fevers, arthritis and 
serositis, and was diagnosed with systemic lupus erythematosus (SLE). She was positive for 
antinuclear antibodies, anti-dsDNA antibodies, antiribonucleoprotein antibodies and anti-Ro 
antibodies. She failed to respond to conventional treatment with azathioprine, 
hydroxychloroquine and methotrexate, and went on to develop lupus nephritis. Increasing 
disease activity led to the commencement of cyclophosphamide and rituximab therapy. 
Despite several cycles of rituximab over a 5-year period she progressed to end-stage renal 
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failure. Her anti-dsDNA antibody levels showed a stepwise increase after almost every 
rituximab infusion despite low numbers of B cells. B-cell numbers and anti-dsDNA antibody 
levels are shown, with rituximab treatments indicated by blue arrows.  
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